Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT00893334Completed

Evaluation of Limb-Girdle Muscular Dystrophy

Showing all 1 trials

Research Network

Active Sponsors

  • Carolinas Medical Center lead study site1
  • Cooperative International Neuromuscular Research Group1

Top Investigators

Related Conditions

  • Becker Muscular Dystrophy1
  • Limbgirdle Muscular Dystrophy Type 2b Miyoshi Myopathy Dysferlin Deficiency1
  • Limbgirdle Muscular Dystrophy Type 2a Calpain3 Deficiency1

Activity Timeline